
Supplementary Material

The Role of Matrix Metalloproteinase-13 (MMP13) in TGFβ/BMP Pathway Regulation of Fibro-Adipogenic Progenitor (FAP) Differentiation

Mengyao Liu^{a,b,c} Brian T. Feeley^{a,b} Hubert T. Kim^{a,b} Xuhui Liu^{a,b}


^aSan Francisco Veterans Affairs Health Care System, Department of Veterans Affairs, San Francisco, CA, USA, ^bDepartment of Orthopaedic Surgery, University of California, San Francisco, CA, USA, ^cCalifornia Northstate University, College of Medicine, Elk Grove, CA, USA **Perilipin A** aSMA


No primary Antibody Control






D







Supplemental Figure 1. FAPs from MMP13 KO mice have increased spontaneous adipogenesis and decreased spontaneous fibrogenesis compared to FAPs from WT mice cultured in the adipogenic medium. A) A typical image of immunostaining for perilipin A and α SMA in FAPs from WT and MMP13 KO mice after 2 weeks of culturing in adipogenic medium. B) FAPs from MMP13 KO mice had significantly higher percentage of perilipin A positive cells compared to FAPs from WT mice. C) FAPs from MMP13 KO mice had a significantly lower percentage of α SMA positive cells compared to FAPs from WT mice. D) Real time PCR showed that FAPs from MMP13 KO mice had a significantly higher expression of Adiponectin and C/EBP compared to FAPs from wildtype mice (* p<0.05). Perilipin A aSMA




MMP-13 Inhibitor











Supplemental Figure 2. Wildtype FAP treated with the MMP13 inhibitor had significantly increased adipogenesis in adipogenic medium. A) A typical image of immunostaining in FAPs treated with 10 μ M MMP13 inhibitor and 0.1% DMSO in the adipogenic medium for 2 weeks. B) WT FAPs treated with the MMP13 inhibitor had a significantly higher percentage of perilipin A (+) cells compared to those treated with DMSO. C) FAPs treated with the MMP13 inhibitor had a significantly reduced the number of α SMA positive cells compared to DMSO. D) Real time PCR showed that FAPs treated with the MMP13 inhibitor had a significantly increased expression of Adiponectin, PPAR γ , and decreased expression of α SMA and Collagen I (* p<0.05).

Perilipin A aSMA

No primary Antibody Control



В



Supplemental Figure 3. MMP13 treatment inhibits FAP adipogenesis and promotes FAP fibrogenesis in adipogenic medium. A) A typical image of immunostaining for FAPs treated with 100ng/ml MMP13 and 0.1% DMSO in adipogenic medium for 2 weeks. B) FAPs treated with MMP13 have a significantly reduced the number of perilipin (+) cells compared to DMSO. C) FAPs treated with MMP13 have a significantly increased the number of α SMA (+) cells compared to the DMSO treatment group. D) Real time PCR results of FAPs treated with MMP13 showed a significantly decreased expression of adipogenesis-related genes (* p<0.05).